Affiliation:
1. Affiliated Hospital of Nantong University
2. The First People's Hospital of Changzhou and The Third Affiliated Hospital of Soochow University
3. Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd
Abstract
Abstract
Tumor-associated macrophages (TAMs) play a critical role in the progression of and immune response to triple-negative breast cancer (TNBC). This study aimed to explore the features of TAMs in TNBCs, construct a risk signature associated with TAM clusters, and verify their relationship with prognosis and immune-related characteristics. Primarily, we selected four TAM clusters and determined the prognosis-related clusters in TNBC based on single-cell RNA sequencing data. Subsequently, TAM-related prognostic genes were identified by univariate Cox regression analysis and an 8-genes risk signature was constructed by LASSO regression. The analysis of immune characteristics showed a significant association between the gene signature and stromal and immune scores as well as immune cells. Multivariate analysis revealed that the risk signature was an independent prognostic factor for TNBC, and confirmed its predictive value for immunotherapeutic outcomes. The newly constructed nomogram integrating stage and TAM-based risk signatures exhibited favorable predictability and reliability for TNBC prognosis prediction. Finally, the increased expression of GPR34, one of the eight hub genes, was explored in TNBC using reverse-transcriptase polymerase chain reaction, western blot, and immunohistochemistry. Our study may allow discovering new independent prognostic factors, updating immunotherapeutic methods, and identifying effective therapeutic targets for TNBC.
Publisher
Research Square Platform LLC
Reference39 articles.
1. Nolan E, Lindeman GJ, Visvader JE (2023) Deciphering breast cancer: from biology to 1. Nolan, E., G.J. Lindeman, and J.E. Visvader, Deciphering breast cancer: from biology to the clinic. Cell, 186(8): p. 1708–1728
2. Advances in systemic therapies for triple negative breast cancer;Leon-Ferre RA;BMJ,2023
3. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer;Liedtke C;J Clin Oncol,2023
4. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial;Liu Y;Cell Res,2023
5. Dynamics and specificities of T cells in cancer immunotherapy;Oliveira G;Nat Rev Cancer,2023